MedPath

EMORY UNIVERSITY

EMORY UNIVERSITY logo
🇺🇸United States
Ownership
Private
Established
1836-12-10
Employees
10K
Market Cap
-
Website
http://www.emory.edu

Clinical Trials

1.4k

Active:62
Completed:802

Trial Phases

6 Phases

Early Phase 1:25
Phase 1:142
Phase 2:204
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1138 trials with phase data)• Click on a phase to view related trials

Not Applicable
580 (51.0%)
Phase 2
204 (17.9%)
Phase 4
146 (12.8%)
Phase 1
142 (12.5%)
Phase 3
41 (3.6%)
Early Phase 1
25 (2.2%)

Got Doxy- 'Flipping the Script' on STI PEP

Not Applicable
Not yet recruiting
Conditions
Sexually Transmitted Infections (STI)
Interventions
Drug: Doxycycline monohydrate 200 mg
Other: Observation
First Posted Date
2025-10-10
Last Posted Date
2025-10-10
Lead Sponsor
Emory University
Target Recruit Count
200
Registration Number
NCT07215325
Locations
🇺🇸

Grady Health System (non-CRN), Atlanta, Georgia, United States

🇺🇸

Hope Clinic, Atlanta, Georgia, United States

Efficacy of EXPAREL vs. Bupivacaine

Not Applicable
Not yet recruiting
Conditions
Total Ankle Arthroplasty
Postsurgical Analgesia
Interventions
First Posted Date
2025-10-08
Last Posted Date
2025-10-08
Lead Sponsor
Emory University
Target Recruit Count
104
Registration Number
NCT07212114
Locations
🇺🇸

Emory University Orthopaedic Hospital Musculoskeletal Institute (MSK), Atlanta, Georgia, United States

Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions

Not Applicable
Not yet recruiting
Conditions
Malignant Skin Neoplasm
Skin Disorder
Skin Neoplasm
First Posted Date
2025-10-08
Last Posted Date
2025-10-08
Lead Sponsor
Emory University
Target Recruit Count
10
Registration Number
NCT07213154
Locations
🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Baricitinib Curative Repression of HIV-1

Not Applicable
Not yet recruiting
Conditions
HIV Infection
HIV
Interventions
Drug: Antiretroviral Therapy (ART)
First Posted Date
2025-10-06
Last Posted Date
2025-10-06
Lead Sponsor
Emory University
Target Recruit Count
20
Registration Number
NCT07209267
Locations
🇺🇸

Grady Infectious Diseases Clinic (Ponce Center), Atlanta, Georgia, United States

🇺🇸

Dr. Gavegnano's Laboratory, Atlanta, Georgia, United States

Quantifying Multi-step Avoidance in Anxiety

Not yet recruiting
Conditions
Anxiety
Anxiety Disorders
First Posted Date
2025-10-02
Last Posted Date
2025-10-02
Lead Sponsor
Emory University
Target Recruit Count
163
Registration Number
NCT07203027
Locations
🇺🇸

Emory College, Atlanta, Georgia, United States

🇺🇸

Facility for Education and Research in Neuroscience (FERN), Atlanta, Georgia, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 271
  • Next

News

Virax Biolabs Partners with Emory University for Long COVID Diagnostic Study Using T Cell Technology

Virax Biolabs has signed a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies of ViraxImmune™ technology for diagnosing long COVID and other post-viral syndromes.

Aligos Therapeutics Initiates Phase 2 Trial of ALG-000184 for Chronic Hepatitis B Treatment

Aligos Therapeutics has begun dosing patients in the Phase 2 B-SUPREME study of ALG-000184, an investigational oral therapy for chronic hepatitis B virus infection.

Psilocybin Shows Anti-Aging Properties in Preclinical Study, Extending Cellular Lifespan by 50%

Emory University researchers demonstrated that psilocin, the active metabolite of psilocybin, extended human skin and lung cell lifespans by more than 50% in laboratory studies.

CDC Sponsors First Clinical Trial of Needle-Free Rotavirus Vaccine Using Dissolvable Microarray Patch Technology

Emory University and Micron Biomedical have launched the first CDC-sponsored clinical trial of a rotavirus vaccine delivered via dissolvable microarray patch technology, marking a significant milestone in needle-free vaccine administration.

Ryght AI Secures $3M Seed Funding and Expands Academic Partnerships to Accelerate Clinical Trial Site Selection

Ryght AI raised $3 million in seed funding led by Foothill Ventures to advance its AI-powered clinical trial platform that creates digital twins of over 100,000 research sites worldwide.

FDA Approves Hundreds of Drugs Without Adequate Evidence of Effectiveness, Investigation Reveals

A two-year investigation found that 73% of the 429 drugs approved by the FDA from 2013-2022 failed to meet the agency's four foundational standards for proving effectiveness.

Long-Term Study Confirms Hydroxyurea's Safety and Efficacy in Pediatric Sickle Cell Disease

Children with sickle cell disease taking hydroxyurea experienced fewer emergency room visits and shorter hospital stays compared to those not on the therapy, according to a study of 2,147 pediatric patients.

Vaccinex's Pepinemab Shows Promise in Turning "Cold" Tumors "Hot" Through Enhanced Immune Response

Vaccinex will present new clinical data at ASCO 2025 showing that neoadjuvant treatment with pepinemab induces mature tertiary lymphoid structures that correlate with improved pathologic response in head and neck cancer patients.

Loneliness Epidemic Shifts: Middle-Aged Americans More Isolated Than Seniors, New Research Reveals

One-third of Americans aged 50-80 report feeling lonely, with rates returning to pre-pandemic levels after peaking at 42% during COVID-19, according to University of Michigan research.

Expanded GLP-1 Drug Access Could Save 42,000 Lives and Billions in Healthcare Costs Annually

Expanding access to GLP-1 weight-loss medications like Ozempic and Zepbound could prevent more than 42,000 deaths annually in the United States, according to a recent Yale study published in PNAS.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.